AstraZeneca could buy Bristol's diabetes stake for more than $3B, report says

12/19/2013 | Reuters

Bristol-Myers Squibb reportedly is considering divesting to partner AstraZeneca its stake in their diabetes joint venture for more than $3 billion. The venture includes oral drugs Onglyza, Kombiglyze and Forxiga as well as injectable treatments Bydureon and Byetta, this article says. Neither firm commented on the report.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT